The body of clinical data that Neuromonics has compiled is unmatched by any other tinnitus treatment provider,” says Duane Knight, chief operating and financial officer with Neuromonics.
Bethlehem, PA (PRWEB) April 18, 2012
For sufferers of tinnitus, the condition described as ringing in the ears when no external sounds are present, treatment and relief have been elusive and inconsistent. Now, Neuromonics, Inc., has issued a comprehensive clinical summary of results to help tinnitus sufferers and providers understand that they can obtain effective treatment.
Neuromonics manufactures and distributes the only FDA-cleared, patented and clinically proven medical device designed for long-term significant relief of tinnitus. Clinically administered and monitored, the Neuromonics Tinnitus Treatment uses the non-invasive device, customized to each patient’s individual audiological profile, to deliver a neural stimulus that targets the brain’s auditory pathways.
The clinical summary, in Word format, is available at Neuromonics’ website, or by requesting a copy by e-mailing rita.walbert(at)neuromonics(dot)com. The summary includes detailed results of Neuromonics Tinnitus Treatment’s clinical efficacy as presented in papers appearing in peer-reviewed medical journals. In addition, the summary outlines nine additional studies that researchers have presented at medical meetings throughout the United States and Europe. Each provides additional evidence of clinical efficacy.
“The body of clinical data that Neuromonics has compiled is unmatched by any other tinnitus treatment provider,” says Duane Knight, chief operating and financial officer with Neuromonics. “The results not only speak to the long-term efficacy of the treatment in a variety of patient groups, but also demonstrate that the Neuromonics Tinnitus Treatment repeatedly achieves clinically significant reductions in tinnitus disturbance and awareness for tinnitus patients.”
The summary provides detail on three clinical trials involving 555 patients who demonstrated a consistent clinical benefit that persisted to 12 months in suitable patients, according to Knight. The peer-reviewed journals and papers in the summary include:
- Ear Nose & Throat Journal, 2008; 87:330-9. “Treatment of tinnitus with a customized acoustic neural stimulus: A controlled clinical study”
- Ear and Hearing, 2007; 28:242-59. “The Neuromonics Tinnitus Treatment: third clinical trial”
- Annals of Otology, Rhinology, and Laryngology, 2008; 117:791-9. “Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: clinical outcomes in general private practice”
- Trends in Amplification, 2008; 12:210-22. “Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: underlying principles and clinical efficacy”
Neuromonics, Inc. (http://www.neuromonics.com)
Based in Bethlehem, Pa., Neuromonics, Inc., manufactures and distributes the FDA-cleared, patented and clinically proven medical device designed for long-term significant relief of tinnitus. With research and development beginning in the early 1990s, the Neuromonics Tinnitus Treatment has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. The treatment has been featured on national news media including “The Doctors” and CNN.